CIK 0001736730 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Camp4 Therapeutics Corp
Sign in to watch- Ticker
- CAMP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-651-8867
- Business address
- 100 TALCOTT AVENUE, SUITE 201, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $39,600
- in 1 filing
- Open-market sales, last 90 days
- $2,504,037
- in 4 filings
Net −$2,464,437. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-25 | Higgins Michael J Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-06-25 | Schwab Andrew J. Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-06-25 | Holtzman Steven H Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-06-25 | Nashat Amir Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-06-25 | Thadhani Ravi I. Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-06-25 | Ragan Paula Director | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-04-01 | Bumcrot David Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2025-04-01 | Maricich Yuri Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2025-04-01 | Gold Kelly Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2025-04-01 | Mandel-Brehm Josh Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +160,000 | 160,000 | ||
| 2025-03-17 | WILLIAMS DOUGLAS E Director | Grant or award · Stock Option (Right to Buy) | +17,787 | 17,787 | ||
| 2025-03-17 | Stewart Murray Director | Grant or award · Stock Option (Right to Buy) | +17,787 | 17,787 | ||
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Conversion | +1,250,061 | 1,250,061 | ||
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Conversion | +87,448 | 87,448 | ||
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Conversion | +353,718 | 1,603,779 | ||
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Conversion | +24,745 | 112,193 | ||
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Purchase | +909,090 | $11.00 | $10.0M | 909,090 |
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Conversion · Series A Prime Preferred Stock | −14,020,475 | 0 | ||
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Conversion · Series A Prime Preferred Stock | −980,829 | 0 | ||
| 2024-10-15 | Polaris Management Co. VII, L.L.C. 10% owner | Conversion · Series B Preferred Stock | −3,967,234 | 0 |
Page 3 of 6 · 111 trades